EGFR and non-small cell lung carcinoma: The results indicated that patients with a short PFS to EGFR-TKIs showed a better response to subsequent anti-PD-1/PD-L1-based immunotherapy in EGFR-mutation NSCLC.[28] Considering these viewpoints, our patient could benefit from ICI due to his high PD-L1 expression, history of smoking, and short PFS to EGFR-TKIs.